Idiopathic pulmonary fibrosis: present understanding and future options.
作者信息
du Bois R M
出版信息
Eur Respir Rev. 2011 Sep 1;20(121):132-3. doi: 10.1183/09059180.00001511.
Abstract
摘要
相似文献
1
Idiopathic pulmonary fibrosis: present understanding and future options.特发性肺纤维化：当前认识与未来选择
Eur Respir Rev. 2011 Sep 1;20(121):132-3. doi: 10.1183/09059180.00001511.
2
A first step against idiopathic pulmonary fibrosis.对抗特发性肺纤维化的第一步。
Eur Respir Rev. 2011 Sep 1;20(121):130-1. doi: 10.1183/09059180.00003711.
3
Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease.超越特发性肺纤维化：进行性肺纤维化性间质性肺疾病的世界。
Eur Respir Rev. 2018 Dec 21;27(150). doi: 10.1183/16000617.0110-2018. Print 2018 Dec 31.
4
Recommendations for evaluating and managing idiopathic pulmonary fibrosis.特发性肺纤维化的评估与管理建议
JAAPA. 2018 Sep;31(9):21-26. doi: 10.1097/01.JAA.0000544299.00459.a4.
5
Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.特发性肺纤维化的最佳支持性治疗：当前的差距和未来的方向。
Eur Respir Rev. 2018 Feb 7;27(147). doi: 10.1183/16000617.0076-2017. Print 2018 Mar 31.
6
Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011.特发性肺纤维化：诊断和临床管理指南已从2000年基于共识的阶段发展到2011年基于证据的阶段。
Eur Respir J. 2011 Apr;37(4):743-6. doi: 10.1183/09031936.00017711.
7
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases.特发性肺纤维化诊断和治疗指南。西班牙肺病学和胸腔外科学会（SEPAR）弥漫性肺疾病研究组。
Arch Bronconeumol. 2013 Aug;49(8):343-53. doi: 10.1016/j.arbres.2013.03.011. Epub 2013 Jun 4.
8
Idiopathic pulmonary fibrosis: combating on a new turf.特发性肺纤维化：在新领域的抗争
Lancet Respir Med. 2016 Jun;4(6):430-2. doi: 10.1016/S2213-2600(16)30106-0. Epub 2016 May 10.
9
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.呼吸急促：在特发性肺纤维化治疗试验中以死亡率作为主要终点：求全责备反难成事。
Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9.
10
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.所有特发性肺纤维化患者都需要进行治疗干预试验吗？赞成与反对的观点。
Respirology. 2015 Apr;20(3):389-94. doi: 10.1111/resp.12484. Epub 2015 Feb 26.
引用本文的文献
1
Identifying TNFSF4-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation.通过调节调节性T细胞分化鉴定出对特发性肺纤维化具有卓越治疗效果的肿瘤坏死因子超家族成员4间充质干细胞。
Stem Cell Res Ther. 2025 Apr 20;16(1):194. doi: 10.1186/s13287-025-04313-6.
2
Telomere Dysfunction in Idiopathic Pulmonary Fibrosis.特发性肺纤维化中的端粒功能障碍
Front Med (Lausanne). 2021 Nov 11;8:739810. doi: 10.3389/fmed.2021.739810. eCollection 2021.
3
Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes.间质基质细胞外泌体通过调节单核细胞表型预防和逆转实验性肺纤维化。
JCI Insight. 2019 Nov 1;4(21):128060. doi: 10.1172/jci.insight.128060.
4
Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.在法国，与所有可用的特发性肺纤维化治疗策略相比，吡非尼酮的成本效益。
J Mark Access Health Policy. 2019 Jun 24;7(1):1626171. doi: 10.1080/20016689.2019.1626171. eCollection 2019.
5
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.特发性肺纤维化治疗的系统评价和网络荟萃分析。
J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S5-S16. doi: 10.18553/jmcp.2017.23.3-b.s5.
6
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future.特发性肺纤维化的药物治疗：从过去到未来。
Eur Respir Rev. 2013 Sep 1;22(129):281-91. doi: 10.1183/09059180.00002113.
7
You say goodbye, and I say hello!你说再见，我说你好！
Eur Respir Rev. 2012 Dec 1;21(126):265-6. doi: 10.1183/09059180.00006112.
8
Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis.肺纤维化发病机制及临床评估的最新进展。
Eur Respir Rev. 2012 Mar 1;21(123):48-56. doi: 10.1183/09059180.00007611.
本文引用的文献
1
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?新兴潜在疗法：特发性肺纤维化患者的新希望？
Eur Respir Rev. 2011 Sep 1;20(121):201-7. doi: 10.1183/09059180.00002011.
2
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points.特发性肺纤维化临床试验中的挑战：终点问题。
Eur Respir Rev. 2011 Sep 1;20(121):195-200. doi: 10.1183/09059180.00001711.
3
Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient.特发性肺纤维化患者的随访和非药物管理。
Eur Respir Rev. 2011 Jun;20(120):114-7. doi: 10.1183/09059180.00001811.
4
Towards a better diagnosis of idiopathic pulmonary fibrosis.朝着更好地诊断特发性肺纤维化迈进。
Eur Respir Rev. 2011 Jun;20(120):108-13. doi: 10.1183/09059180.00001611.
5
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
6
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.伊马替尼治疗特发性肺纤维化：随机安慰剂对照试验结果。
Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.
7
Pirfenidone in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
8
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.干扰素γ-1b对特发性肺纤维化患者生存的影响（INSPIRE）：一项多中心、随机、安慰剂对照试验
Lancet. 2009 Jul 18;374(9685):222-8. doi: 10.1016/S0140-6736(09)60551-1. Epub 2009 Jun 29.
9
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.用依那西普治疗特发性肺纤维化：一项探索性、安慰剂对照试验。
Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55. doi: 10.1164/rccm.200709-1446OC. Epub 2008 Jul 31.
10
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.BUILD-1：波生坦治疗特发性肺纤维化的随机安慰剂对照试验。
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81. doi: 10.1164/rccm.200705-732OC. Epub 2007 Sep 27.
Zotero 插件